Found: 26
Select item for more details and to access through your institution.
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
- Published in:
- Arthritis Research & Therapy, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13075-024-03337-2
- By:
- Publication type:
- Article
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 5, p. 529, doi. 10.1002/jcph.2360
- By:
- Publication type:
- Article
Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 8, p. 4409, doi. 10.3390/ijms25084409
- By:
- Publication type:
- Article
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 2, p. 156, doi. 10.1001/jamadermatol.2023.4990
- By:
- Publication type:
- Article
Natural History of Keloids: A Sociodemographic Analysis Using Structured and Unstructured Data.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 1, p. 131, doi. 10.1007/s13555-023-01070-3
- By:
- Publication type:
- Article
Role of Innate Immunity in Allergic Contact Dermatitis: An Update.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 16, p. 12975, doi. 10.3390/ijms241612975
- By:
- Publication type:
- Article
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 8, p. 1370, doi. 10.1002/art.42519
- By:
- Publication type:
- Article
Performance of Modified ALMS and BLISS Criteria with Standard of Care Treatment in Two US Health Care Systems.
- Published in:
- Arthritis Care & Research, 2023, v. 75, n. 7, p. 1423, doi. 10.1002/acr.25025
- By:
- Publication type:
- Article
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 33, doi. 10.1093/bjd/ljad098
- By:
- Publication type:
- Article
Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes re-pigmentation of stable lesions in patients with active nonsegmental vitiligo: results from a phase 2b, randomized, placebocontrolled, dose-ranging study.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. i1, doi. 10.1093/bjd/ljac106.002
- By:
- Publication type:
- Article
Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: results from a phase 2b, randomized, doseranging study with an extension period.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. i3, doi. 10.1093/bjd/ljac106.004
- By:
- Publication type:
- Article
Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study*.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 6, p. 878, doi. 10.1111/bjd.21826
- By:
- Publication type:
- Article
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2077, doi. 10.1007/s13555-022-00764-4
- By:
- Publication type:
- Article
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 2, p. 671, doi. 10.1111/cts.12929
- By:
- Publication type:
- Article
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
- Published in:
- Arthritis & Rheumatology, 2020, v. 72, n. 10, p. 1621, doi. 10.1002/art.41316
- By:
- Publication type:
- Article
A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2020, v. 13, p. 259, doi. 10.2147/CCID.S245649
- By:
- Publication type:
- Article
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study.
- Published in:
- British Journal of Clinical Pharmacology, 2018, v. 84, n. 8, p. 1776, doi. 10.1111/bcp.13612
- By:
- Publication type:
- Article
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 4, p. 434, doi. 10.1002/jcph.1046
- By:
- Publication type:
- Article
Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Reproductive Immunology: a Focus on the Role of Female Sex Hormones and Other Gender-Related Factors.
- Published in:
- Clinical Reviews in Allergy & Immunology, 2011, v. 40, n. 1, p. 1, doi. 10.1007/s12016-010-8209-z
- By:
- Publication type:
- Article
Prolactin, Systemic Lupus Erythematosus, and Autoreactive B Cells: Lessons Learnt from Murine Models.
- Published in:
- Clinical Reviews in Allergy & Immunology, 2011, v. 40, n. 1, p. 8, doi. 10.1007/s12016-009-8182-6
- By:
- Publication type:
- Article
Reproductive Immunology: Current Status and Future Directions (Part I).
- Published in:
- Clinical Reviews in Allergy & Immunology, 2010, v. 39, n. 3, p. 143, doi. 10.1007/s12016-009-8181-7
- By:
- Publication type:
- Article
Prolactinoma and systemic lupus erythematosus: do serum prolactin levels matter?
- Published in:
- Clinical Rheumatology, 2006, v. 25, n. 4, p. 602, doi. 10.1007/s10067-005-0117-x
- By:
- Publication type:
- Article
Relapsing arterial aneurysms in juvenile Behçet’s disease.
- Published in:
- Clinical Rheumatology, 2005, v. 24, n. 1, p. 72, doi. 10.1007/s10067-004-0967-7
- By:
- Publication type:
- Article